Alkermes (ALKS) is down -10.7%, or -$3.61 to $30.20.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Phase 2 narcolepsy study details ‘scant,’ says Truist
- Alkermes Announces Positive Results from Vibrance-2 Study
- Alkermes down 14% at $29.00 after Vibrance-2 Phase 2 alixorexton study data
- Alkermes’ Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating
- Alkermes says ‘positive’ results from Vibrance-2 Phase 2 study of alixorexton